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Abstract
Background: Plasminogen activator inhibitor-1 (PAI-1), a major regulator of the plasmin-based pericellular proteolytic
cascade, is significantly increased in human arterial plaques contributing to vessel fibrosis, arteriosclerosis and thrombosis,
particularly in the context of elevated tissue TGF-b1. Identification of molecular events underlying to PAI-1 induction in
response to TGF-b1 may yield novel targets for the therapy of cardiovascular disease.
Principal Findings: Reactive oxygen species are generated within 5 minutes after addition of TGF-b1 to quiescent vascular
smooth muscle cells (VSMCs) resulting in pp60
c-src activation and PAI-1 expression. TGF-b1-stimulated Src kinase signaling
sustained the duration (but not the initiation) of SMAD3 phosphorylation in VSMC by reducing the levels of PPM1A, a
recently identified C-terminal SMAD2/3 phosphatase, thereby maintaining SMAD2/3 in an active state with retention of PAI-
1 transcription. The markedly increased PPM1A levels in triple Src kinase (c-Src, Yes, Fyn)-null fibroblasts are consistent with
reductions in both SMAD3 phosphorylation and PAI-1 expression in response to TGF-b1 compared to wild-type cells.
Activation of the Rho-ROCK pathway was mediated by Src kinases and required for PAI-1 induction in TGF-b1-stimulated
VSMCs. Inhibition of Rho-ROCK signaling blocked the TGF-b1-mediated decrease in nuclear PPM1A content and effectively
attenuated PAI-1 expression. TGF-b1-induced PAI-1 expression was undetectable in caveolin-1-null cells, correlating with the
reduced Rho-GTP loading and SMAD2/3 phosphorylation evident in TGF-b1-treated caveolin-1-deficient cells relative to
their wild-type counterparts. Src kinases, moreover, were critical upstream effectors of caveolin-1
Y14 phosphoryation and
initiation of downstream signaling.
Conclusions: TGF-b1-initiated Src-dependent caveolin-1
Y14 phosphorylation is a critical event in Rho-ROCK-mediated
suppression of nuclear PPM1A levels maintaining, thereby, SMAD2/3-dependent transcription of the PAI-1 gene.
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Introduction
Plasminogen activator inhibitor type-1 (PAI-1, SERPINE1) is a
major causative factor of arterial thrombosis and perivascular
fibrosis [1–4] as well as a biomarker and prognostic indicator of
cardiovascular disease-related death [5]. Transgenic mice that
overexpress PAI-1 develop age-related vessel fibrosis and athero-
sclerosis while PAI-1-deficient animals are protected from
experimentally-induced vascular disease [2,6–9]. Since PAI-1 is
involved in TGF-b1-stimulated neointima formation and lesion
progression [10–12], clarifying the signaling network underlying
TGF-b1-induced PAI-1 expression may provide novel selective
targets to attenuate TGF-b1/PAI-1-associated cardiovascular
pathologies.
Cooperation between non-SMAD (i.e., pp60
c-Src- EGFR-
ERK1/2) and SMAD signaling is required to initiate maximal
TGF-b1-induced transcriptional activation of profibrotic genes
such as PAI-1 and CTGF [4,13–15]. SMAD2/3 phosphorylation
is dependent on the ALK5 type I receptor following TGF-b1
ligand-receptor engagement although the maintenance of SMAD
phosphorylation and, likely, SMAD function are regulated both
positively and negatively by collateral mechanisms [16]. TGF-b1-
stimulated Rho-ROCK activation, for example, impacts the
duration (but not the initiation) of SMAD2/3 activity but the
underlying molecular basis and relationship to TGF-b1 target
gene transcription is unknown. TGF-b1-mediated Rho-activation,
furthermore, is repressed in caveolin-1-deficient cells, perhaps due
to caveolin-1/caveolae-dependent TGF-b1 receptor interactions
and internalization [17]. Caveolin-1 is required for TGF-b1-
mediated fibronectin expression in mesangial cells [18], however,
suggesting that caveolin-1 regulation of TGF-b1 signaling may be
cell type-specific.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22896This paper provides novel evidence that TGF-b1 stimulation of
VSMC leads to a reduction in nuclear levels of PPM1A, a recently
identified C-terminal SMAD2/3 phosphatase capable of attenu-
ating TGF-b1-mediated transcriptional responses including PAI-1
expression [19]. Inhibition of Rho-ROCK signaling prior to
addition of TGF-b1 rescues PPM1A expression with correlative
decreases in nuclear pSMAD2/3 content implicating the Rho-
ROCK pathway as an upstream negative regulator of this serine
phosphatase. SMAD2/3 phosphorylation and subsequent PAI-1
induction by TGF-b1 was suppressed by genetic deficiency of
caveolin-1 implicating caveolin-1 as an activator of Rho-ROCK-
SMAD2/3 signaling. Src kinase activity, moreover, was critical for
caveolin-1
Y14 phosphorylation as assessed using mouse embryo
fibroblasts deficient in Src, Yes, Fyn kinases (SYF
2/2/2), by
introduction of a wild-type pp60
c-Src construct in SYF
2/2/2 cells
and use of src kinase inhibitors. Significantly reduced SMAD3
phosphorylation and increased PPM1A expression in SYF
2/2/2
cells, relative to wild-type fibroblasts correlated with reduced PAI-
1 levels. Src kinase-dependent FAK phosphorylation at Y577 and
Y861, moreover, is stimulated by TGF-b1 while TGF-b1-initiated
FAK
Y397 autophosphorylation was Src-independent. FAK is
required for caveolin-1
Y14 phosphorylation, pSMAD3 activation
and PAI-1 induction. Finally, stimulation of the Src-FAK-caveolin-
1-SMAD3 signaling axis and subsequent PAI-1 expression in
response to TGF-b1 requires generation of reactive oxygen species
(ROS) linking alterations in cellular redox state to gene
reprogramming. TGF-b1 increases the production of ROS likely
through several NADPH oxidases (NOXs) of which Nox4 has
been linked to PAI-1 expression through mitogen-activated
protein kinase phosphatase-1 inhibition [20]. While JNK and
p38 appear implicated in the TGF-b1RROS pathway of PAI-1
gene control, integration of other non-canonical SMAD-depen-
dent events are less clear and are the subject of this study.
Materials and Methods
Cell Culture
Primary rat aortic VSMCs (gift of Dr. H. Singer, Albany
Medical College) were cultured in DMEM/F-12 (1:1) medium
containing 10% FBS. R22 rat VSMCs (gift of Dr. P.A. Jones,
USC/Norris Comprehensive Cancer Center) were grown in low
glucose (1 g/l) DMEM supplemented with 10% FBS. Triple src
family kinase (c-src,c - yes,c - fyn)-deficient MEFs (SYF
2/2/2) as well
as SYF
2/2/2 cells engineered to re-express pp60
c-src (also from Dr.
H. Singer), caveolin-1-null MEFs and their wild-type counterparts
(provided by Dr. P.J. McKeown-Longo, Albany Medical College)
and FAK-deficient MEFs and corresponding wild-type cells (gift of
Dr. J. Zhao, Albany Medical College) were propagated in DMEM
containing 10% FBS. Conditions for serum-deprivation and TGF-
b1 stimulation for each cell type is described in the text as is
pretreatment with SU6656 (src family kinase inhibitor), Y-27632
(p160ROCK inhibitor), SIS3 (SMAD3 inhibitor) (all from
Calbiochem). Inhibitors of free radical generation, N-acetyl
cysteine (NAC) and diphenyleneiodonium chloride (DPI), were
from Sigma-Aldrich.
Western Blotting
VSMCs and MEFs were disrupted in 4% SDS/PBS for
10 minutes, lysates vortexed briefly, boiled for 5 minutes then
centrifuged at 14,000 rpm for 15 minutes. Aliquots (30 mg cellular
protein) were electrophoretically-separated, transferred to nitrocel-
lulose, membranes blocked in 5% milk in 0.05% Triton-X 100/
PBS, incubated overnight with specific antibodies to rat PAI-1
(American Diagnostica), EGFR, pEGFR
Y845, pSMAD2
Ser465/467,
SMAD2/3, pSMAD3
Ser423/425, pp60
c-src-pY416 (Cell Signaling);
pERK1/2, ERK2, pSMAD 2/3, FAK, RhoA, TGF-bRI (Santa
Cruz Biotechnology), phosphotyrosine (4G10, Upstate Biotechnol-
ogy), caveolin-1, phospho-caveolin-1
Y14 (BD Bioscience),
pFAK
Y397, pFAK
Y577, pFAK
Y861 (Biosource), and human PAI-1
(#9163)inblockingbuffer and washed threetimesin0.05%Triton-
X 100/PBS prior to incubation with secondary antibodies.
Immunoreactive proteins were visualized with ECL reagent and
quantitated by densitometry. Stripped membranes were reprobed
withantibodies to actin,EGFR, caveolin-1,RhoA,ERK2,pp60
c-src,
SMAD2 or SMAD2/3 to confirm protein loading levels. Statistical
analysis of quantitative data from scanned blots was done by t-test.
Immunohistochemistry and Immunocytochemistry
Tissue sections of human carotid artery plaques (gift of Dr. M.
Lennartz, Albany Medical College) were de-paraffinized in 3
changes of xylene (5 mins each), placed in 2 changes of 100%
ethanol (3 mins each), hydrated in progressively-diluted ethanol
95%(3 mins),70%(3 mins)and 50%(3 mins)andrinsedindistilled
water. Slides were immersed in sodium citrate buffer (10 mM
sodium citrate, 0.05% Tween 20, pH 6.0), heated at 95–100uC for
15 minutes then cooled to room temperature. Following several
PBS washes, sections were blocked with 10% normal goat serum for
1 hour, incubated in primary antibodies to PAI-1 (#9163) and a-
smooth muscle actin (10 mg/ml; Sigma Aldrich), diluted in 1%
BSA/PBS, washed in PBS (3 times, 5 mins each), then incubated in
appropriate secondary antibodies (Molecular probes; Alexa series)
diluted in 1% BSA in PBS for 1 hour. After final washing in PBS
(365 mins each), sections were mounted with ProLong antifade-
gold+DAPI. For immunocytochemistry, serum-deprived semi-
confluent MEFs and VSMCs were stimulated with TGF-b1
(2 hours) and processed for immunofluorescence as described
previously [13,15]. Briefly, cells were fixed in 3% paraformalde-
hyde, permeabilized in 0.25% Triton X-100, blocked in goat serum
then overlayed with antibodies to caveolin-1 or pcaveolin-1 (1:200)
for a 1 hour incubationat 37uC. Following3 PBS washes, cells were
incubated in Alexa 488-labeled secondary antibodies prior to final
rinsing and mounting as detailed above.
Rho GTPase Assay
PBS-washed cells were extracted in 25 mM HEPES, pH 7.5,
150 mM NaCl, 1 mM EDTA, 10% glycerol containing leupeptin
and 1 mM sodium orthovanadate) by constant agitation for
15 minutes at 4uC. Clarified lystates (600 mg protein) were
incubated with Rhotekin RBD-agarose beads for 45 minutes at
4uC. Active (i.e., Rhotekin-bound) Rho and total Rho levels (GTP-
Rho+GDP-Rho) were determined by western blotting with RhoA
antibodies.
Transient Transfection of siRNA or Dominant-Negative
(DN) Constructs
Semi-confluent (70%) primary VSMC cultures were washed in
PBS prior to addition of siRNA constructs to GFP (control),
SMAD3, caveolin-1 or PPM1A (Dharmacon; final concentration
1 mM), in Accell siRNA delivery medium (1 ml) for 72–96 hours.
Following a brief incubation in serum-free DMEM, VSMCs were
stimulated with TGF-b1 for 4 hrs prior to harvesting for
extraction. Subconfluent 35-mm cultures of R22 cells were
transfected with DN-pp60
c-src, DN-RhoA
N17 or control GFP
expression constructs as described [13–15]. Following transfection,
cells were serum-deprived for 2 days prior to TGF-b1 stimulation.
Transfection efficiency was 50–70% (assessed by GFP fluorescence
microscopy).
PAI-1 Induction Requires Src and Caveolin-1
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22896Figure 1. PAI-1 induction in response to TGF-b1 involves reactive oxygen species (ROS). DCF fluorescence measurements (as described in
Methods) were used to determine ROS generation (per equivalent number of cells) and expressed relative to unstimulated cultures (set as a.u.=1).
ROS levels increase within 5 minutes after addition of TGF-b1 (1 ng/ml) to serum-deprived quiescent VSMCs (A). ROS generation appears to be
important in TGF-b1-stimulated PAI-1 expression since PAI-1 induction is effectively suppressed by even low concentrations of the established
inhibitors of free radical generation NAC (B) and DPI (C). NAC pretreatment also attenuates (at 2 mM) and completely eliminates (at concentrations
$5 mM) TGF-b1-dependent ERK1/2 and SMAD2/3 phosphorylation but has no effect of EGF-stimulated ERK1/2 activation (E). Both NAC (B,F,G) and
DPI (C,H) pretreatment (30 mins) served to assess the role of ROS in TGF-b1- and EGF-mediated PAI-1 induction. ERK2 provided a loading control.
Data plots (A,D,F) represent the mean 6 S.D. of three independent experiments; statistical significance among the indicated groups was calculated
by t-test.
doi:10.1371/journal.pone.0022896.g001
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Wild-type caveolin-1 (Cav-1
WT) pLHCX retroviral expression
constructs [18] were transfected into sub-confluent caveolin-1
2/2
MEFs using Lipofectimine (1:3 DNA/lipid ratio) in DMEM for
6 hours. Following overnight recovery in DMEM/10% FBS,
transfectants were selected in hygromycin (200–350 mg/ml) for 5–
7 days.
Immunoprecipitation
Cells were disrupted for 30 min (in cold 50 mM HEPES,
pH 7.5, 1% Triton X-100, 1% NP-40, 0.5% deoxycholate,
150 mM NaCl, 50 mM NaF, 1 mM Na-orthovanadate, 0.1%
SDS, protease cocktail inhibitor) and extracts clarified at 14,000 g
for 15 min. Lysate protein (500 mg) from control and TGF-b1-
treated cells were incubated with antibodies to RhoA (2 mg, RhoA;
Santa Cruz Biotechnology) for 2 h in a total volume of 500 ml.
Immune complexes were collected with Protein A/G Plus-agarose,
washed three times with lysis buffer without SDS and boiled in
sample buffer.
Reactive Oxygen Species (ROS) Assay
The carboxy derivative of fluorescein, 29,79-dichlorofluorescein
(carboxy-H2DCFDA) (Molecular probes; C400) was used to
determine ROS generation in response to TGF-b1 according to
manufacturer’s recommendations. Briefly, cells were stimulated
with TGF-b1 for the times indicated, medium removed and cells
incubated with 5 mM DCFDA in PBS for 15 minutes prior to
scrape harvest. Equivalent number of cells were used to assess
baseline fluorescence (unstimulated) and response to TGF-b1
stimulation with a multi-detection microplate reader (Synergy HT;
Bio-Tek) at an excitation wavelength of 495 nm.
Results
ROS are rapidly generated (within 5 minutes) in response to
TGF-b1( Figure 1A). Pretreatment of VSMCs with NAC (a
glutathione precursor) (Figure 1B) or DPI (which inhibits nitric
oxide synthetase and NADPH oxidase) (Figure 1C) effectively
suppressed PAI-1 induction by TGF-b1 (summarized in
Figure 1D) and reduced TGF-b1-mediated ERK1/2 as well as
SMAD2/3 activation (Figure 1E). NAC, however, did not affect
EGF-stimulated ERK1/2 phosphorylation (Figure 1E) and, in
contrast to requirements for TGF-b1 induction, neither NAC
(Figure 1F,G) or DPI (Figure 1H) blocked EGF-stimulated PAI-
1 expression. The involvement of ROS in PAI-1 gene control is
clearly stimulus-dependent.
Since changes in redox state by TGF-b1 affects both the
canonical SMAD and non-canonical pathways (e.g., Figure 1E),
it was important to clarify the impact on downstream TGF-b1
effectors (e.g., src, EGFR, FAK, caveolin-1, SMADs). NAC
effectively suppressed TGF-b1-induced c-Src
Y416 as well as
FAK
Y577 (a target of activated c-Src kinases) phosphorylation
(Figure 2A), positioning ROS upstream of c-Src -and FAK-
mediated signaling. While TGF-b1-stimulated caveolin-1
Y14
phosphorylation is also NAC sensitive, FAK
Y397 autophosphory-
lation is only marginally affected by NAC pretreatment suggesting
the participation of non-ROS-dependent mechanisms in FAK
auto-activation (Figure 2A). Time-course assessments indicated,
moreover, that NAC preincubation suppressed both the amplitude
and duration of SMAD3 phosphorylation as well as the inhibition
of PAI-1 induction (cf., Figures 1E,2B). Consistent with
suppression of SMAD3 phosphorylation, PAI-1 induction by
TGF-b1 is also effectively attentuated by NAC preincubation
(Figure 1D,2B).
Given the importance of Src kinases as downstream effectors of
ROS- sensitive pathways [21], the Src-dependency of TGF-b1-
initiated signaling was further assessed using Src, Yes, Fyn triple-null
(SYF
2/2/2) and wild-type (SYF
+/+/+) MEFs. c-Src protein as well
as c-Src
Y416 phosphorylation was evident, as expected, in TGF-b1-
stimulated wild-type but not SYF-null cells (Figure 3A). EGFR
activation in response to TGF-b1, moreover, is significantly
diminished in SYF
+/+/+ compared to SYF
2/2/2 fibroblasts
consistent with involvement of Src kinases in TGF-b1-mediated
EGFR transactivation in VSMCs [13–15]. SMAD3 phosphoryla-
tion (both extent and duration) is also significantly reduced in
SYF
2/2/2 cells compared to their wild-type counterparts over the
Figure 2. Inhibition of ROS generation attenuates TGF-b1
signaling in VSMC. Quiescent VSMCs were stimulated with TGF-b1
(1 ng/ml) for the times indicated with or without NAC (5 mM)
pretreatment for 1 hour. Increases in pSrc
Y416, pFAK
Y577 and pCaveo-
lin
Y14 (targets of c-Src kinases) in response to TGF-b1 is completely
inhibited by NAC, suggesting an upstream role for ROS generation in
activation of Src/FAK/caveolin-1 signaling pathways (A). FAK
Y397
phosphorylation by TGF-b1 (at least within the time frame of 2 hours)
is relatively unaffected by NAC blockade of ROS generation. Total levels
of c-Src, FAK and caveolin-1 are largely unchanged over the time course
of TGF-b1 exposure serving as loading controls (A). To assess the role of
ROS generation in SMAD3 activation, TGF-b1-stimulated SMAD3
phosphorylation over time was compared to an identical window with
NAC pretreatment. Blots were probed with antibodies to determine
both pSMAD3 and total SMAD3 levels (B).
doi:10.1371/journal.pone.0022896.g002
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22896time course of TGF-b1-stimulation and PAI-1 induction is
completely eliminated in Src kinase-deficient MEFs (Figure 3B).
This is in keeping with the higher levels of PPM1A evident in
SYF
2/2/2 relative to wild-type fibroblasts. VSMC pretreatment
with the src kinase-specific inhibitor SU6656, as expected,
prevented the TGF-b1-dependent increase in c-Src
Y416 phosphor-
ylation (Figure 3C). SU6656, however, did not impact TGF-b1-
initiated SMAD2/3 activation at early time points (e.g., 1 hour)
but completely eliminated later-stage (e.g., 4 hrs) SMAD2/3
phosphorylation (Figure 3C). Transient transfection of VSMCs
Figure 3. Downstream signaling events initiated by TGF-b1-activated Src kinase. SYF
+/+/+ and SYF
2/2/2 fibroblasts were serum-deprived
for 1 day prior to stimulation with TGF-b1 (0.1 ng/ml) for the times indicated and lysates subject to western analysis. Src activation (assessed using
phospho- Src
Y416 antibodies) and increased EGFR phosphorylation at the Src kinase target Y845 site, are both evident in TGF-b1-stimulated wild-type
(SYF
+/+/+) MEFs but not Src, Fyn, Yes triple-null (SYF
2/2/2) cells (A). The level (at 15 and 30 minutes) and maintenance (at 4 hrs) of SMAD3
phosphorylation is significantly reduced in SYF
2/2/2 fibroblasts compared to their wild-type counterparts (B). In contrast to the typical time course-
dependency of PAI-1 induction in response to TGF-b1 in SYF
+/+/+ cells, PAI-1 was not detectable in Src-deficient MEFs regardless of the duration of
TGF-b1 exposure. The absence of PAI-1 expression and attenuated SMAD3 phosphorylation reflected increased PPM1A levels in SYF
2/2/2 as
compared to SYF
+/+/+ fibroblasts (B). Pretreatment of VSMCs with the Src kinase inhibitor SU6656 (2 mM) blocked the long-term maintenance (but not
the initiation) of SMAD2/3 phosphorylation in response to TGF-b1 while total SMAD levels remain unchanged (C). Src
Y416 phosphorylation by TGF-b1
was completely eliminated by SU6656 confirming the effectiveness of this inhibitor (C). Transient transfection of VSMCs with a dominant-negative
pp60
c-src (DN-Src) expression construct (or a GFP control vector) 72 hours prior to incubation with TGF-b1 for 6 hours was followed by western
analysis for PAI-1. TGF-b1-stimulated PAI-1 induction was effectively suppressed by the DN-Src but not the GFP construct (D). SYF
2/2/2 cells
genetically-engineered to express wild-type pp60
c-src (SYF
2/2/2+WT Src) rescued PAI-1 inducibility in response to TGF-b1( E). ERK2 (A,D,E) and
SMAD3 (C) serve as a loading controls.
doi:10.1371/journal.pone.0022896.g003
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22896Figure 4. FAK is a downstream target of Src kinases and is required for PAI-1 induction by TGF-b1. MEFs were serum-deprived for 1 day
prior to addition of TGF-b1 (0.1 ng/ml). TGF-b1 stimulates FAK phosphorylation at the Y577 and Y861 sites in SYF
+/+/+ but not SYF
2/2/2cells
consistent with an upstream role of Src kinases in FAK activation. TGF-b1-induced FAK
Y397 autophosphorylation, in contrast, is unaffected by genetic
ablation of src family kinases (A). To assess the role of FAK in TGF-b1-induced PAI-1 and CTGF expression, serum-deprived FAK
+/+ and FAK
2/2 MEFs
were stimulated with TGF-b1 and blots probed with antibodies to PAI-1 and CTGF (B). TGF-b1 stimulates FAK phosphorylation at Y397, Y561 and
Y861 only in wild-type but not, as anticipated, in FAK-null fibroblasts (C) providing antibody specificity controls for panels A–C. TGF-b1-stimulated c-
Src and EGFR activation is significantly attenuated in FAK
2/2 cells relative to FAK
+/+ MEFs (C). SMAD3 C-terminal phosphorylation in response to TGF-
b1 is reduced in FAK
2/2 as compared to FAK
+/+ cells; total SMAD2/3 levels were unchanged regardless of FAK genetic status (D). Western analysis
was used to evaluate the effect of FAK genetic status (FAK
2/2 vs. FAK
+/+) on TGF-b1-induced caveolin-1
Y14 phosphorylation (D). Consistent with
previous observations [40], total caveolin-1 is lower in FAK
2/2 MEFs compared to wild-type cultures (D). Assessment of total FAK (A,B), ERK2 (B,C)
and SMAD3 (D) provided loading controls.
doi:10.1371/journal.pone.0022896.g004
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22896with a dominant-negative c-Src construct, furthermore, effectively
inhibited PAI-1 expression upon TGF-b1 addition (Figure 3D).
Stable reconstitution of wild-type pp60
c-src in SYF
2/2/2 cells
(SYF
2/2/+WT-Src) wassufficient to ‘‘rescue’’ TGF-b1-mediated PAI-
1 inducibility (Figure 3E) confirming participation of pp60
c-src
in PAI-1 gene control.
Since TGF-b1 stimulates FAK tyrosine phosphorylation (at
Y397, Y577 and Y861), it was necessary to assess whether Src
kinases are upstream regulators of this response reminiscent of Src-
FAK involvement in adhesion-based signaling (e.g., [22–25]).
pFAK
Y397 levels were similar in SYF
2/2/2 cells and wild-type
fibroblasts suggesting that TGF-b1-initiated FAK autophosphory-
lation is largely Src-independent (Figure 4A). However, TGF-b1-
initiated FAK
Y577 and Y861 phosphorylations are not evident in
SYF
2/2/2 fibroblasts compared to wild-type MEFs confirming a
role for Src kinases in FAK activation in response to TGF-b1. FAK
is critical, moreover, for both TGF-b1-induced PAI-1 and CTGF
expressionasneitheraredetectableinFAK-nullMEFs(Figure4B).
TGF-b1-induced FAK
Y397,Y577,Y861 phosphorylation is also evident
in FAK
+/+ MEFs (similar to VSMCs) but not in their null
counterparts as anticipated (Figure 4C). FAK appears critical,
moreover, for optimal c-Src kinase activation by TGF-b1 since
Src
Y416 phosphorylation is dramatically decreased in FAK
2/2
fibroblasts compared to wild-type cells. FAK
2/2 MEFs, further-
more, do not increase EGFR
Y845 phosphorylation in response to
TGF-b1 consistent withan upstream role of c-Src and FAKin TGF-
Figure 5. Caveolin-1 is required for TGF-b1-induced PAI-1 expression. Serum-deprived (1 day) caveolin-1
+/+ and caveolin-1
2/2 MEFs were
stimulated with TGF-b1 (0.1 ng/ml) for 2 or 4 hours and blots probed with antibodies to PAI-1, pSMAD2 and pERK1/2. PAI-1 induction is apparent in
wild-type but not in caveolin-1-deficient cells (A,B). TGF-b1-induced SMAD2 phosphorylation is decreased while ERK1/2 activation is increased in
caveolin-1-null compared to wild-type fibroblasts at comparable time points (A,C). Exposure to TGF-b1 (T) was for 4 hours in (B) and for 2 or 4 hours
in (C). Introduction of a wild-type caveolin-1 construct (+WT Cav-1) in caveolin-1-null cells rescues TGF-b1 inducibility of PAI-1 unlike caveolin-1
2/2
MEFs expressing GFP (+GFP) (D). VSMCs were transfected with control or caveolin-1 siRNA constructs and, after a brief period of serum deprivation,
stimulated with TGF-b1 for 4 hours. Cellular lysates were separated by electrophoresis and blots probed with antibodies to PAI-1, caveolin-1 and actin
(as a loading control) (E). Histograms (B,C) depict the mean 6 S.D. of three independent experiments.
doi:10.1371/journal.pone.0022896.g005
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22896Figure 6. c-Src is an upstream regulator of caveolin-1
Y14 phosphorylation. MEFs were serum-deprived for 1 day prior to incubation with
TGF-b1 (0.1 ng/ml) for the times indicated. Western analysis indicated that TGF-b1 stimulated caveolin-1 phosphorylation at the Y14 c-Src kinase
target site in caveolin-1
+/+ fibroblasts but not, as expected, in caveolin-1
2/2 cells (A,B). Caveolin
Y14 phosphorylation is similarly evident extracts of
SYF
+/+/+ but not in SYF
2/2/2 MEFs (C). Stable expression of a pp60
c-src construct (+WT Src) in SYF
2/2/2 fibroblasts is sufficient to rescue caveolin
Y14
phosphorylation in response to TGF-b1 (but not in empty vector expressing SYF
2/2/2 cells) despite comparable caveolin-1 expression in both cell
types (D). Pretreatment of serum-deprived VSMC with the Src kinase inhibitor SU6656 (2 mM) prior to addition of TGF-b1 (1 ng/ml) eliminated TGF-b1-
induced Src
Y416 activation, caveolin
Y14 phosphorylation and PAI-1 expression (E). Total ERK2 (A,B), caveolin-1 (C,D,E) and c-Src (E) were
approximately constant under all culture conditions providing internal loading controls. Data plotted in (B) represent the mean 6 S.D. of three
independent experiments. To assess potential growth factor-associated changes in caveolin-1 localization, subconfluent serum-deprived MEFs were
stimulated with TGF-b1 (0.1 ng/ml) for 2 hrs and the distribution of phospho-caveolin-1
Y14 and total caveolin-1 assessed by immunocytochemistry;
control cells remained untreated (F).
doi:10.1371/journal.pone.0022896.g006
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also impacted other TGF-b1 signal intermediates as well. SMAD3
activation in TGF-b1-treated FAK
2/2 cells is substantially reduced
compared to wild-type MEFs despite equivalent SMAD3 protein
levels regardless of genetic background (Figure 4D).
The TGF-b1-dependent increase in caveolin-1
Y14 phosphory-
lation was similarly attenuated by FAK deficiency with conse-
quences on TGF-b1 signaling (Figure 4D) since caveolin-1
2/2
cells have a significantly decreased PAI-1 inductive response
compared to Cav-1
+/+ MEFs (Figure 5A,B). The level and time
course of TGF-b1-stimulated SMAD2/3 activation were both
decreased in caveolin-1
2/2 fibroblasts (as was the case in NAC- or
SU6656-treated cells as well as in SYF
2/2/2 or FAK
2/2 cells),
while ERK1/2 phosphorylation, in contrast, is increased
(Figure 5A,C). Stable re-introduction of a wild-type caveolin-1
construct (WT cav-1) in caveolin-1
2/2 cells rescued PAI-1
expression (Figure 5D) confirming a role of caveolin-1 in TGF-
b1 signaling in fibroblasts. Consistent with these findings, transient
siRNA-mediated knockdown of caveolin-1 expression effectively
suppressed PAI-1 induction in TGF-b1-stimulated VSMCs
compared to control siRNA-transfected cultures (Figure 5E).
The functional state of caveolin-1 is subject to modulation by
Y14 phosphorylation, by subcellular location (e.g., caveolae, focal
contacts or lipid rafts), or by expression levels [26–29]. TGF-b1-
induced caveolin-1
Y14 phosphorylation is evident within 1–2 hrs in
wild-type MEFs but not, as anticipated, in caveolin-1-null cells
(Figure 6A,B). Since caveolin-1
Y14 is a substrate of the Abelson
(Abl) and Src kinases, albeit under different restrictions [26], the
role of Src in caveolin Y14 site targeting in the context of TGF-b1
stimulation was assessed. Caveolin-1
Y14 phosphorylation in
response to TGF-b1 was undetectable in SYF
2/2/2 cells
(Figure 6C). Stable re-expression of pp60
c-src in SYF
2/2/2 cells
rescued caveolin-1
Y14 phosphorylation as well as PAI-1 induction
(Figure 3B,6D). To assess if caveolin-1
Y14 phosphorylation in
VSMCs is similarly mediated by Src kinases, quiescent cultures
were pretreated with SU6656 (2 mM) prior to addition of TGF-b1.
TGF-b1-stimulated caveolin-1
Y14 phosphorylation, c-Src
Y416 site
activation and subsequent PAI-1 expression were completely
eliminated by SU6656 (Figure 6E). Caveolin-1 trafficking also
appears to be phosphorylation state-dependent as phospho-
caveolin-1 redistributed to focal adhesion-like peripheral structures
within 2 hrs of TGF-b1 stimulation (Figure 6F) indicating that
changes in subcellular distribution occur within the real time of
PAI-1 induction.
To investigate downstream targets of caveolin-1 in transducing
TGF-b1 signals, focus centered on RhoA as TGF-b1 stimulates
Rho GTP loading (Figure 7A). Caveolin-1 interacts with RhoA in
response to TGF-b1( Figure 7B,C) and active RhoA (2–4 hrs post
TGF-b1 stimulation) is markedly reduced in caveolin-1
2/2
compared to wild-type fibroblasts despite equivalent RhoA levels
(Figure 7A). Transient expression of a DN-RhoA construct or pre-
incubation with the ROCK inhibitor Y-27632 eliminated PAI-1
induction by TGF-b1 establishing the signaling relevance of an
intact RhoA-ROCK pathway in PAI-1 gene control (Figures 7D,
8A). Time-course and dose-response assessments indicated, further-
more, that ROCK inhibition only marginally affected TGF-b1-
induced pSMAD2/3 levels at one hour but completely blocked
SMAD2/3 phosphorylation and nuclear accumulation at 4 hours
(Figure 8A–C) suggesting that the Rho-ROCK pathway impacts
not the initiation but the maintenance of SMAD2/3 phosphory-
lation. SMAD3 is,in fact,a critical downstreameffectorof TGF-b1-
dependentPAI-1expressionasSMAD3knockdown(Figure8D,E)
or pre-treatment with SIS3 (a selective inhibitor of SMAD3
phosphorylation) (Figure 8D,E) completely suppressed PAI-1
induction in VSMCs (Figure 8D; not shown)a sw e l la si nM E F s
(Figure8F,G).NuclearlevelsofpSMAD3increase overthe4 hour
time course response to TGF-b1 stimulation as expected; Y-27632
preincubation virtually eliminated pSMAD3 nuclear accumulation
coincident with elevations in the nuclear content of the C-terminal
pSMAD phosphatase PPM1A (Figure 8H). Addition of Y-27632
prior to TGF-b1 stimulation rescued nuclear levels of PPM1 to that
approximating control conditions with the corresponding charac-
teristic decrease in nuclear pSMAD3 evident at 4 hours post-TGF-
b1 addition (Figure 8C,H). These data suggest that ROCK
regulates PPM1A levels modulating, thereby, pSMAD3 nuclear
abundance. Consistent with the concept that PPM1A is a negative
Figure 7. RhoA both interacts with caveolin-1
Y14 in response to
TGF-b1 and required for PAI-1 induction. A Rho-GTPase assay (as
described in Methods) was used to assess relative RhoA activation by
TGF-b1 in fibroblasts. RhoA-GTP loading increased within 2–4 hours of
TGF-b1 addition (0.1 ng/ml) to 1-day serum-deprived wild-type MEFs. In
contrast, the level and duration of RhoA activation during this 4 hour
window is markedly reduced in caveolin-1-null fibroblasts compared to
caveolin-1
+/+ cells (A). Immunoprecipitation (IP) of RhoA followed by
phospho-caveolin-1
Y14 western analysis disclosed a time-dependent
association between phospho-caveolin-1
Y14 and endogenous RhoA in
response to TGF-b1 while total levels of caveolin-1 remain unchanged
(B). IP of caveolin-1 followed by western blotting for RhoA similarly
confirmed increased interaction between both proteins in wild-type
(WT) MEFs upon a 2 to 4 hr stimulation with TGF-b1 but not in caveolin-
null cells (C). Transfection of a dominant-negative RhoA construct prior
to addition of TGF-b1 effectively inhibited PAI-1 expression while
introduction of a GFP control vector was without effect (D) indicating
that RhoA is required for TGF-b1-induced PAI-1 expression.
doi:10.1371/journal.pone.0022896.g007
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e22896regulator of TGF-b1/SMAD2/3 signaling, suppression of endog-
enous PPM1A in VSMCs with siRNA constructs further augments
TGF-b1-induced PAI-1 expression compared to identically-stimu-
lated control siRNA transfectants(Figure 8I). Collectively, these
findings implicate PPM1A in TGF-b1 signaling pathways in
VSMCs.
Figure 8. Rho-ROCK pathway regulates nuclear levels of PPM1A and maintains SMAD3 activation. VSMCs maintained under serum-
deprived conditions for 1 day were TGF-b1-stimulated (1 ng/ml) with or without the ROCK inhibitor, Y-27632 (10 mm) and cellular lysates probed for
pSMAD2, total SMAD2/3, PAI-1 and ERK2 (A). Late-stage (4 hour) pSMAD2 levels were markedly attenuated and PAI-1 expression completely inhibited
by ROCK blockade (A). TGF-b1-induced SMAD phosphorylation at the late time points (4 hours) is significantly reduced by inhibition of ROCK signaling.
Serum-deprived VSMCs were pretreated for 30 minutes with Y-27632 (at indicated concentrations) prior to exposure to TGF-b1 for 4 hours. Cell lysates
were probed for PAI-1, SMAD2/3, pSMAD2/3 and PPM1A (C). PAI-1 expression in response to TGF-b1 was completely blocked by Y-27632 pre-exposure
(10 mM final concentration) despite the initial increase in SMAD2 phosphorylation in Y-27632-treated cells. Concentrations of Y-27632 that effectively
inhibit PAI-1 induction and suppress SMAD2 phosphorylation also increase PPMIA levels (C). Transient knock-down of SMAD3 with siRNA constructs (as
detailed in Methods) (D,E) or pre-incubation with the small molecule inhibitor of SMAD3 phosphorylation SIS3 (5 mM) [41] (D,F,G) eliminates TGF-b1-
inducedPAI-1 expression in VSMCs (D,E) andMEFs (F,G). Cell fractionation studies confirmedthat nuclearaccumulationof pSMAD3 in responseto TGF-
b1 is blocked while nuclear PPM1A content increased upon pre-incubation with Y-27632 (H). TGF-b1 stimulation for 4 hours actually reduced nuclear
PPM1A levels, which was restored by Y-27632 pretreatment (H). siRNA-mediated PPM1A knockdown in VSMCs resulted in a significantly increased TGF-
b1-inducedPAI-1 responsecomparedtocells transfected withcontrol siRNAconstructs (I).ERK2 (A,B,D–G),SMAD2/3 (A,C,F), tubulin (D), lamin(H) and
actin (I) provide loading controls. Data plotted in (B,E,G) is the mean 6 S.D. of three independent experiments.
doi:10.1371/journal.pone.0022896.g008
Figure 9. A model for TGF-b1 stimulated maintenance of SMAD3 phosphorylation and PAI-1 induction via Src/FAK/Caveolin-1 signaling.
TGF-b1 stimulates caveolin-1
Y14 phosphorylation in a reactive oxygen species-FAK/c-Src dependent manner removing repressive influences on EGFR signaling
(in red) leading to EGFR transactivation (also by c-Src), thereby, initiating signaling events leading to the MEK-ERK pathway activation necessary for PAI-1
induction. Src kinase phosphorylation of caveolin-1
Y14 also stimulates Rho-GTP loading and ROCK (an established downstream target of Rho) activation is
necessary for PAI-1 induction. pCaveolin-1
Y14-Rho-ROCK mediated signaling leads to inhibition of PTEN-PPM1A interactions resulting in a reduction of nuclear
PPM1A phosphatase (black pathway), thereby, maintaining the pSMAD2/3 levels (highlighted in blue) required for PAI-1 induction by TGF-b1( s e et e x t ) .P A I - 1i s
elevated in atherosclerotic plaques frequently colocalizing with a-smooth muscle actin-expressing cells, presumably VSMCs (insert).
doi:10.1371/journal.pone.0022896.g009
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VSMCs contribute to neointima formation, arteriosclerosis and
vascular remodeling, particularly in the context of elevated tissue
TGF-b1a n dP A I - 1( Figure 9) [1,11,12,30]. TGF-b1-induced
genetic reprogramming utilizes SMAD as well as non-SMAD
cascades [13,14,31–33] and while the function of SMADs as
transcriptional regulators of TGF-b1 signaling is well established
(e.g., [34]), how non-SMAD elements (e.g., Rho-ROCK, Src,
FAK, caveolin-1) integrate into canonical SMAD pathways may
be both cell type- and target gene-dependent. ROS generation
stimulated by TGF-b1 appears to be a central element in the
mobilization of the Src-FAK-caveolin-1-Rho-ROCK sequence
leading to the maintenance of SMAD-dependent transcriptional
mechanisms in VSMCs and embryonic fibroblasts. Clearly, ROS
participation in ERK1/2 phosphorylation and PAI-1 gene
control differs as a function of the specific stimulus (i.e., TGF-
b1 vs. EGF). pp60
c-src kinase activation in response to TGF-b1,
furthermore, is required for EGFR
Y845 phosphorylation and
subsequent PAI-1 gene induction via ERK1/2 dependent
mechanisms in VSMCs [14,15]. ROS-stimulated Src kinase
activity, moreover, maintains SMAD3-dependent signaling,
highlighting a central role of Src kinases in the regulation of
both canonical (SMAD-centric) and non-canonical (e.g., EGFR-
ERK/RhoA-ROCK) cascades that cooperate to attain maximal
PAI-1 expression [14].
Src kinases are upstream effectors of both FAK and caveolin-1
activation as FAK
Y577 and Y861 and caveolin-1
Y14 phosphorylation
upon TGF-b1 stimulation is not detected in triple-deficient
SYF
2/2/2 cells. Stable reconstitution of pp60
c-Src expression in
SYF-null cells rescued caveolin-1
Y14 phosphorylation and PAI-1
induction in response to TGF-b1. Moreover, FAK also impacts
caveolin-1
Y14 site phosphorylation in the TGF-b1 signaling
cascade since phospho-caveolin
Y14 is undetectable in FAK
2/2
cells. TGF-b1 fails to induce PAI-1 in caveolin-1
2/2 fibroblasts
while re-expression of a wild-type caveolin-1 construct in caveolin-
1-deficient cells effectively rescued TGF-b1 inducibility of this
serine protease inhibitor. Although gene-specific pathways down-
stream of caveolin-1 are only beginning to be defined, RhoA
interacts with caveolin-1 in response to TGF-b1 and its activation
is regulated by caveolin-1 as this response is attenuated in
caveolin-1-null fibroblasts. These observations are also consistent
with the requirements for fibronectin induction by TGF-b1i n
mesangial cells which also involves src-caveolin-1-RhoA signaling
[18]. Moreover, TGF-b1-stimulated PAI-1 expression in hepato-
cytes similarly requires caveolin-1-dependent signaling and
SMAD2/3 activity [25].
Negative regulators of SMAD signaling also impact transcrip-
tional and biological outcomes [16]. Src-deficient fibroblasts
exhibit elevated expression PPM1A (a SMAD phosphatase) which
accounts, at least in part, for reduced pSMAD levels as well as
attenuated PAI-1 induction in response to TGF-b1, Indeed,
ectopic overexpression of PPM1A in HaCaT keratinocytes
suppressed, while shRNA depletion of PPM1A enhanced, PAI-1
transcription in response to TGF-b1 [19]. How PPM1A is
regulated and its specific role in TGF-b1-driven pathophysiologic
disorders (e.g., cardiovascular disease, tissue fibrosis, cancer
progression/invasion) is not known. Long-term (4 hour) TGF-
b1-stimulation reduced nuclear levels of PPM1A in VSMCs,
consistent with observations that TGF-b1-induced proteosomal
degradation of PPM1A involves attenuation of PPM1A-PTEN
(phosphatase and tensin homologue) interactions [35]. Inhibition
of Rho/ROCK signaling, moreover, prevented the TGF-b1-
induced reduction in nuclear PPM1A levels, suggesting that the
Rho-ROCK pathway positively mediates PPM1A degradation
likely accounting for maintenance of nuclear pSMAD3 necessary
for PAI-1 induction. PTEN activity and cellular location is also
regulated by Rho kinases and ROCK can directly phosphorylate
PTEN facilitating PTEN-Rho-ROCK interactions [36]. Complex
formation may destabilize PTEN-PPM1A interactions. One
model consistent with current data suggests that Rho phosphor-
ylates PTEN causing dissociation of PTEN-PPM1A complexes
resulting in PPM1A degradation, thereby, retaining SMAD
transcriptional activity (Figure 9). PTEN knockdown, moreover,
results in hyper-induction of PAI-1 expression in response to TGF-
b1 [37] and PTEN deletion in fibroblasts is sufficient to induce
PAI-1 and cellular senescence [38,39]. Recent findings suggest
that TGF-b1 induces a ‘‘senescence-like’’ growth arrest, at least in
primary VSMCs, with accompanying increases in p21, PAI-1 and
CTGF expression (unpublished). Current studies focus on
evaluation of the role of PAI-1, induced via ROS/caveolin-1/
SMAD-dependent signaling, in this response.
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